Glucagon-like peptide-1 receptor agonists approved for use in the United States
| Drug | Available doses | Frequency and route | Dose approved for weight management |
|---|---|---|---|
| Exenatide | 5 μg, 10 μg | Twice daily subcutaneously | Not approved |
| Liraglutide | 0.6 mg, 1.2 mg, 1.8 mg | Once daily subcutaneously | 0.6 mg once daily for 1 week, increase by 0.6 mg daily at weekly intervals to a target dose of 3 mg once daily |
| Exenatide extended-release | 2 mg | Once weekly subcutaneously | Not approved |
| Dulaglutide | 0.75 mg, 1.5 mg, 3 mg, 4.5 mg | Once weekly subcutaneously | Not approved |
| Semaglutide | 0.25 mg, 0.5 mg, 1 mg, 2 mg | Once weekly | Titrate every 4 weeks: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg once weekly |
| Semaglutide, oral | 3 mg, 7 mg, 14 mg | Once daily by mouth | Not approved |
| Liraglutide-insulin degludec | 0.36 mg-10 U 0.5 mg-16 U | Once daily subcutaneously | Not approved |
| Lixisenatide-insulin glargine | 5 μg-15 U 10 μg-30 U | Once daily subcutaneously | Not approved |
| Tirzepatide | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg | Once weekly subcutaneously | Not approved |